NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohns disease: a preliminary report
Rev. esp. enferm. dig
; 102(10): 591-595, oct. 2010. tab, ilus
Artigo
em Inglês
| IBECS
| ID: ibc-82201
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Introduction:
adalimumab is a recombinant fully-human monoclonal immunoglobulin (IgG1) antibody utilized in the treatment of Crohn´s disease. Unfortunately no clinical or genetic markers exist to predict response to anti-tumor necrosis factor-alpha (TNF) therapy. The aim of this study was to evaluate the association between selected genes involved in cytokine regulation and response to adalimumab treatment in Crohns disease.Methods:
twenty-four patients with Crohns disease either naïve (n = 8) or had lost response or were unable to tolerate the chimeric anti-TNF antibody infliximab (n=16) were enrolled in the study. Patients were genotyped for main polymorphisms in NOD2, CD14 and TLR4 genes. Response to adalimumab treatment was defined as a decrease of Crohns disease activity index of at least 100 points or a closure of at least 50% of fistulas in case of fistulizing Crohns disease.Results:
overall, 75% of patients did respond to treatment. However, no statistically significant association was found between any of the genotypes and the response to adalimumab.Conclusions:
in our small study group no association between the studied polymorphisms and response to adalimumab was apparent. Systematic studies to search for genetic markers of response to anti-TNF therapy are necessary(AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Terapia Biológica
/
Receptores de Lipopolissacarídeos
/
Proteína Adaptadora de Sinalização NOD2
Tipo de estudo:
Estudo prognóstico
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Rev. esp. enferm. dig
Ano de publicação:
2010
Tipo de documento:
Artigo
Instituição/País de afiliação:
University Hospital of Santiago de Compostela/Spain
/
VU University Medical Center/The Netherlands